MedPacto Signs Business Agreement with Theragen Etex to Expand Anti-Cancer New Drug Business

MedPacto announced on the 10th that it signed a business agreement with Theragen Etex at its headquarters in Seocho-dong, Seoul, to expand its anticancer drug business.

On the morning of the 10th, officials are taking a commemorative photo at the business agreement ceremony held at the Medfact headquarters in Seocho-dong, Seoul, to expand the anticancer new drug business. From the left, Seongjin Kim, CEO of Medfact; Jinup Go, Chairman of Theragen Etex; and Sihong Park, CEO of Theragen Etex.
[Photo by Medfact]

원본보기 아이콘

The signing ceremony was attended by MedPacto CEO Kim Sung-jin and Theragen Etex CEOs Ko Jin-up and Park Si-hong, along with executives from both companies.

MedPacto explained that this agreement, linking the innovation, practical application, and commercialization of anticancer new drugs, is expected to strengthen the anticancer drug business capabilities of both companies. Additionally, it added that cooperation for the global market launch of domestic new drugs and the enhancement of corporate value for both companies are also anticipated.

A MedPacto official stated, "Strengthening cooperation with Theragen Etex in the anticancer drug business is expected to lead to enhanced new drug research and development capabilities, including anticancer drugs, that MedPacto possesses."

A Theragen Etex official explained the agreement, saying, "It aims to promote efficient development, production, and sales of anticancer new drugs," and added, "This is a future growth business agreement intended to support MedPacto’s successful anticancer drug development and, based on that, Theragen Etex’s expansion and leadership in the domestic anticancer drug market."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.